Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone Participatns with Relasped Refractory or Ineligible for Autologous Stem Cell Transplant
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
June 20, 2018
End Date
September 9, 2020
Administered By
Duke Cancer Institute
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
June 20, 2018
End Date
September 9, 2020